ZOE.F Zoetis Inc. R

Healthcare · Drug Manufacturers - Specialty & Generic

9 · Forte Momentum 0.0 · Fraco Atenção sequência de 12a

61.76

-1.37%

Sobre a empresa

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Ver mais

Site

2.95%

33.77%

1.82

25.5B

11.46

5.39

84.50

Faixa de 52 semanas

61.8

mín 61.1 máx 128

Análise aprofundada do dividendo

Zoetis Inc., a Healthcare sector company specializing in Drug Manufacturers - Specialty & Generic, currently offers a dividend yield of 2.95% in EUR. This yield is significantly above its 5-year average of 0.87% and its 5-year high of 1.35%. Valuation analysis suggests the stock is currently undervalued according to Yield Theory, though its fair value calculation indicates the price is 4.6% above fair value, suggesting a "fair" margin of safety. Momentum and value scores are not available, nor is an overall rating score.

Histórico de dividendos

Zoetis has a history of consistent dividend increases, maintaining a streak of 12 consecutive years. The company has demonstrated strong dividend growth with a 3-year compound annual growth rate (CAGR) of 15.44% and a 5-year CAGR of 20.11%. Annual dividends per share in EUR have increased steadily: 0.2539 in 2014, 0.3703 in 2017, 0.5783 in 2019, 0.8816 in 2021, 1.1461 in 2022, 1.3224 in 2023, and projected to 1.7632 in 2025. It is recognized as a Dividend Contender.

Segurança do dividendo

The dividend appears well-covered with a payout ratio of 33.77% based on earnings per share. In terms of leverage, Zoetis has a debt-to-equity ratio of 293.996%.

Quantic · Grátis

Leia o resto sobre a segurança do dividendo

Mais os riscos principais e o que observar em seguida. Grátis, sem cartão.

Experimente uma carteira de exemplo Cadastre-se grátis

Gerado por IA a partir dos dados de dividendos da Quantic · Atualizado em 29 Set 2026 · Informação, não aconselhamento financeiro.

Exibido em inglês — uma tradução está a caminho.